CsA inhibits LTα mRNA levels in anti-CD3 or anti-CD28 activated PBMCs.

PBMCs were treated with 5 ng/mL anti-CD3 antibodies (aCD3), 5 ng/mL anti-CD28 antibodies (aCD28), or 5 ng/mL anti-CD3 plus 5 ng/mL anti-CD28 antibodies in the presence (+) or absence (−) of CsA (400 nM), as indicated. CsA was added 30 minutes prior to activation. See Figure 1 and “Materials and methods” for details.